LncRNA ABHD11‐AS1 promotes the development of endometrial carcinoma by targeting cyclin D1

Liu, Yao; Wang, Lili; Chen, Shuo; Zong, Zhi‐Hong; Guan, Xue; Zhao, Yang

doi:10.1111/jcmm.13675

Cited by 37 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We 19 and others have shown that lncRNAs can directly interact with key signaling proteins to regulate their function. It was reported that lncRNA ABHD11-AS1 38 interacted with Cyclin D1 and promoted the growth of endometrial cancer cells, but the mechanism was unclear. LncRNA was also shown to regulate the transcription of CCND1 39 .…”

Section: Discussionmentioning

confidence: 99%

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer

Shi

et al. 2020

Nat Commun

136

View full text Add to dashboard Cite

Cyclin D1 is one of the most important oncoproteins that drives cancer cell proliferation and associates with tamoxifen resistance in breast cancer. Here, we identify a lncRNA, DILA1, which interacts with Cyclin D1 and is overexpressed in tamoxifen-resistant breast cancer cells. Mechanistically, DILA1 inhibits the phosphorylation of Cyclin D1 at Thr286 by directly interacting with Thr286 and blocking its subsequent degradation, leading to overexpressed Cyclin D1 protein in breast cancer. Knocking down DILA1 decreases Cyclin D1 protein expression, inhibits cancer cell growth and restores tamoxifen sensitivity both in vitro and in vivo. High expression of DILA1 is associated with overexpressed Cyclin D1 protein and poor prognosis in breast cancer patients who received tamoxifen treatment. This study shows the previously unappreciated importance of post-translational dysregulation of Cyclin D1 contributing to tamoxifen resistance in breast cancer. Moreover, it reveals the novel mechanism of DILA1 in regulating Cyclin D1 protein stability and suggests DILA1 is a specific therapeutic target to downregulate Cyclin D1 protein and reverse tamoxifen resistance in treating breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer

Shi

et al. 2020

Nat Commun

136

View full text Add to dashboard Cite

show abstract

“…Cyclin D1 is an important mediator of cancer initiation, development, and metastasis and is associated with poor prognosis. LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1[ 26 ]. Interfering with cyclin D1 leads to PI3K/Akt signal suppression [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Bu Shen Yang Xue Prescription Has Treating Effect on Endometrial Cancer through FSH/PI3K/AKT/Gankyrin/HIF‐α/cyclinD 1 Pathway in Ishikawa Cells

Chen

Fei

Zhu

2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. The formulation of Bu Shen Yang Xue (BSYX) has been clinically used in treating gynecologic disease in China, especially for the development of the endometrium. Endometrial carcinoma is the most common malignant tumor of the female genital tract in developed countries. And few studies have been reported on the antitumor activity of BSYX. Therefore, this study aimed to investigate the effect of BSYX on endometrial cancer and make an initial discussion of the underlining mechanisms in Ishikawa cells. Methods and Results. Firstly, 60 SPF female nude mice were randomly divided into control group, model group, BSYX group, and positive group. The models of subcutaneous tumor xenograft of nude mice were established by injection of human endometrial carcinoma cell line Ishikawa tumor cell suspension. Compared with model group, BSYX reduced effectively tumor volume and changed pathological feature in mice tumor issue. Meanwhile, proteins from tumor issues were detected by western blot analysis. The protein levels of follicle-stimulating hormone receptor (FSHR), p-Akt/Akt, Gankyrin, and cyclinD1 in the model group were higher than those in control group but the expression in BSYX group was lower than that in the model group. The hypoxia inducible factor alpha (HIF-α) protein level in the model group was lower than those in control group and upregulated in BSYX group. In addition, Ishikawa cells were cultured and then exposed to follicle-stimulating hormone (FSH), LY294002, a highly selective PI3K inhibitor and serum containing BSYX, respectively. LY294002 and BSYX markedly decreased the cancer cell viability and migration ability and increased the apoptosis rate. FSH promoted the cancer cell ability and migration ability. LY294002 and BSYX evidently downregulated the proteins levels of FSHR, p-Akt/Akt, Gankyrin, and cyclinD1 and upregulated the expression of HIF-α protein, and FSH was on the opposite. Conclusions. Taken together, our results showed that the formulation of BSYX had antitumor effect on endometrial cancer in vivo and in vitro and was related with FSH/PI3K/AKT/Gankyrin/HIF-α/cyclinD1 transduction pathway.

show abstract

“…SNHG5 promotes CRC cell survival by counteracting STAU1-mediated mRNA destabilization [25]. LncRNA ABHD11 Antisense RNA 1 (ABHD11-AS1) has been identified to act as diagnostic and prognostic bio-markers as well as therapeutic target in endometrial carcinoma, ovarian cancer, bladder cancer, gastric cancer [7–10]. However, the roles and underlying mechanisms of ABHD11-AS1 was unknown in CRC.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…LncRNA ABHD11 antisense RNA 1 (ABHD11-AS1), locating at the human chromosome 7 q11.23, has been identified as one oncogene in various cancer [7–10]. For instance, Liu et al demonstrated that lncRNA ABHD11-AS1 stimulates cell proliferation and invasion of endometrial carcinoma [7]. Moreover, lncRNA ABHD11-AS1 promotes the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long non-coding RNA ABHD11-AS1 promotes colorectal cancer development through regulation of miR-133a/SOX4 axis

Lei

Duan

2018

Bioscience Reports

View full text Add to dashboard Cite

Recently, lncRNA has been verified to regulate the development and progression of tumor. LncRNA ABHD11-AS1 has been proven to serve as an oncogene in several cancers. However, the role of ABHD11-AS1 in colorectal cancer remains totally unknown. In the present study, qRT-PCR assay revealed that ABHD11-AS1 expression was markedly higher in colorectal cancer tissues and cell lines. In addition, patients who displayed overexpression of ABHD11-AS1 showed a significantly poorer progression free survival (PFS) and overall survival (OS) by Kaplan–Meier analysis. Loss-of-function experiments suggested that silencing of ABHD11-AS1 expression could significantly reduce the proliferation, colony formation, migration and invasion of colorectal cancer cells, and increase cell apoptosis. Moreover, bioinformatics analysis, biotin pull-down assay, luciferase reporter assay, and RIP assay disclosed that ABHD11-AS1 straightly interacted with miR-133a. We also found that SOX4 was a downstream target of miR-133a and ABHD11-AS1 subsequently exerted its biological effects via modulating the expression of SOX4 in colorectal cancer cells. Collectively, these findings manifested that the ABHD11-AS1/miR-133a/SOX4 axis may be a cogitable and promising therapeutic target for colorectal cancer.

show abstract

LncRNA ABHD11‐AS1 promotes the development of endometrial carcinoma by targeting cyclin D1

Cited by 37 publications

References 27 publications

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer

Bu Shen Yang Xue Prescription Has Treating Effect on Endometrial Cancer through FSH/PI3K/AKT/Gankyrin/HIF‐α/cyclinD 1 Pathway in Ishikawa Cells

Long non-coding RNA ABHD11-AS1 promotes colorectal cancer development through regulation of miR-133a/SOX4 axis

Contact Info

Product

Resources

About